Disease relevance of Fomocain

• Effects and toxicity of new fomocaine derivatives and of 2-hydroxypropyl-beta-cyclodextrin inclusion compounds in rats [1].
• Obviously the paresis of N. ischiadicus is less pronounced after administration of the inclusion compounds. c) The cyclodextrin formulations of the new meta-fomocaines (OL/4 and OL/40) are, compared to the complexed fomocaine, without practically relevant LA effect [1].
• Based on the results of the in vitro experiments, some of the most active fomocaine derivatives were also tested for their ability to prevent aconitine-induced arrhythmias in the anaesthetized rat [2].

High impact information on Fomocain

• In vitro interactions with the Cytochrome P450 system, toxicity, and local anaesthetic effects of Fomocaine Alkylmorpholine derivatives in rats [3].
• Basing on standard methods for testing of LA effects and using two methods to characterising toxicity of LA (paresis of the N. ischiadicus, LD50) it can be concluded that: a) The good surface anaesthesia caused by fomocaine is not surpassed by its alkylmorpholine derivatives OW1-11 [1].
• In the case of O/G 5, agonistic effects of both enantiomers could be shown. d) Fomocaine undergoes extensive biotransformation with subsequent formation of 14 metabolites [4].

Chemical compound and disease context of Fomocain

• LD50 determinations in mice revealed that these two agents show a lower acute toxicity than lidocaine and propafenone while being somewhat more toxic than quinidine and fomocaine [2].

Biological context of Fomocain

• On the basis of the experiments with fomocaine derivatives, distinct structure-activity relationships could be demonstrated for fomocaine derivatives concerning a) LA effects and b) toxicity [5].

Analytical, diagnostic and therapeutic context of Fomocain

• 1. The metabolism of fomocaine following its oral administration to male and female Wistar rats and male beagle dogs has been qualitatively investigated [6].

References